Turn Therapeutics heads into its May 14 earnings report with a quiet but telling signal: every insider trade on record points in the same direction.
A cluster of buys from the Acting CFO and a director accumulated over 77,000 net shares across the late 2025 period, at prices ranging from $2.61 to $4.95. That accumulation happened in the months following the stock's worst post-earnings drop on record — a 9% single-day fall in November 2025 that extended to a 38% drawdown over the following five days. Buying into that kind of reaction is a meaningful signal of internal conviction, even if the dollar amounts are modest. The stock has since recovered, closing at $3.88 — up 16% over the past month and 4.6% on the week.
The borrow market tells a relaxed story heading into the print. Availability is ample — over 1,000% of short interest remains available to lend, well into what ORTEX considers loose territory. Cost to borrow has roughly halved since late March, falling from nearly 4% to just 1.5%. Short interest itself, at just 0.6% of the free float, is too small to matter as a directional signal. What's notable is the recent pickup in shares short — up roughly 22% over the past week — but with absolute levels this low and borrow this cheap, the move is more likely noise than a conviction short. The ORTEX short score of 36.3 reflects a similarly relaxed read: no squeeze pressure, no unusual demand for borrows.
Turn Therapeutics is a pre-revenue biotech. Net income runs at an estimated -$3.8 million, with zero top-line revenue. That makes this a pipeline-driven print, not a financial one. Ownership is heavily concentrated — the top individual holder controls 52.8% of shares — which means the float is thin and any catalyst-driven move could be amplified by limited liquidity. Institutional presence beyond the founding-level holders is minimal, with Millennium Management holding a small position initiated as of December 2025.
The prior earnings history offers two data points. March 2026 produced a 3% one-day decline before a 4% five-day recovery. November 2025 produced the sharp drop. The May 14 print will test whether the pipeline narrative that drove insiders to buy through that November dip has advanced enough to hold the recent recovery in price.
See the live data behind this article on ORTEX.
Open TTRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
